CALLABLE KICK-IN GOAL LINKED TO WORST OF - ROCHE GS/LONZA GROUP/GIVAUDAN Stock

Certificat

KNEQDU

CH1229772632

Market Closed - Swiss Exchange 11:20:00 2023-05-17 EDT
98.7 CHF -0.25% Intraday chart for CALLABLE KICK-IN GOAL LINKED TO WORST OF - ROCHE GS/LONZA GROUP/GIVAUDAN
3 months-2.08%
Current year+0.15%

Static data

Product typeObligations Convertibles
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer UBS
KNEQDU
ISINCH1229772632
Date issued 2022-12-07
Strike 301.2 CHF
Maturity 2024-06-07 (5 Days)
Parity 0.06 : 1
Emission price 100 CHF
Emission volume N/A
Settlement les deux
Currency CHF

Technical Indicators

Highest since issue 101.6 CHF
Lowest since issue 98.35 CHF
Spread 50 CHF
Spread %1.01%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
231 CHF
Average target price
277.5 CHF
Spread / Average Target
+20.14%
Consensus
  1. Stock Market
  2. Certificates
  3. KNEQDU Certificat